During the last session, Lexicon Pharmaceuticals Inc (NASDAQ:LXRX)’s traded shares were 2.11 million, with the beta value of the company hitting 1.04. The 52-week high for the LXRX share is $3.73, that puts it down -440.58 from that peak though still a striking 10.14% gain since the share price plummeted to a 52-week low of $0.62. The company’s market capitalization is $251.24M, and the average trade volume was 4.88 million shares over the past three months.

Lexicon Pharmaceuticals Inc (LXRX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.71. LXRX has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it.

Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) trade information

The stock’s 5-day price performance is -7.02%, and it has moved by -1.53% in 30 days. Based on these gigs, the overall price performance for the year is -69.78%.

The consensus price target of analysts on Wall Street is $6, which implies an increase of 88.5% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $6 and $6 respectively. As a result, LXRX is trading at a discount of -769.57% off the target high and -769.57% off the low.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 6.80%. While earnings are projected to return 14.05% in 2025, the next five years will return 19.31% per annum.

LXRX Dividends

Lexicon Pharmaceuticals Inc is due to release its next quarterly earnings in March. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

The next largest institutional holding, with 38.69 million shares, is of FMR LLC’s that is approximately 15.7656% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $64.99 million.